{"id":20,"date":"2018-08-31T08:43:31","date_gmt":"2018-08-31T08:43:31","guid":{"rendered":"http:\/\/fertiga.com\/?page_id=20"},"modified":"2026-06-04T10:12:33","modified_gmt":"2026-06-04T08:12:33","slug":"increased-live-birth-rate-2","status":"publish","type":"page","link":"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/","title":{"rendered":"Pour les prestataires de soins de sant\u00e9"},"content":{"rendered":"<\/p>\n<p class=\"has-text-align-center\"><em>Tous les ovocytes ne sont pas \u00e9gaux\u2026 mais vous pouvez d\u00e9sormais d\u00e9terminer lesquels se d\u00e9velopperont le mieux.<\/em><\/p>\n<p>\n\n\n<p class=\"wp-block-paragraph\">L\u2019Aurora niPCT\u2122 est le premier <strong>test non invasif, cliniquement prouv\u00e9,<\/strong> qui examine ce qui compte vraiment : le potentiel biologique de l\u2019ovocyte lui-m\u00eame. En analysant les cellules cumulus qui entourent et soutiennent naturellement l'\u0153uf, Aurora niPCT\u2122 d\u00e9code les signaux mol\u00e9culaires au potentiel le plus \u00e9lev\u00e9. Contrairement aux \u00e9valuations bas\u00e9es sur l\u2019imagerie ou la culture, <strong>il ne devine pas : il mesure<\/strong>. Contrairement aux tests g\u00e9n\u00e9tiques invasifs, il est <strong>sans danger<\/strong>. Et contrairement \u00e0 de nombreux outils \u00e9mergents, il est <strong>d\u00e9j\u00e0 valid\u00e9 en pratique clinique<\/strong>, o\u00f9 il permet d'augmenter significativement les taux de grossesse et de naissances vivantes d\u00e8s le premier transfert.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\">La <strong>pr\u00e9cision du test Aurora niPCT\u2122 pour une naissance vivante<\/strong> chez les patientes stimul\u00e9es par<\/h2>\n\n\n\n<div class=\"stats-container\">\n  <div class=\"stat-item\">\n    <div class=\"stat-box\">\n      <span class=\"stat-text\">hMG <span class=\"small-brackets\">(par exemple Menopur, Meriofert)<\/span><\/span>\n      <span class=\"stat-bubble\">\n        80%*\n        <svg class=\"bubble-ring\" viewbox=\"0 0 100 100\">\n          <circle cx=\"50\" cy=\"50\" r=\"48\" stroke=\"#528C9E\" stroke-width=\"4\" fill=\"none\"\/>\n        <\/svg>\n      <\/span>\n    <\/div>\n  <\/div>\n  <div class=\"stat-item\">\n    <div class=\"stat-box\">\n      <span class=\"stat-text\">rFSH <span class=\"small-brackets\">(par exemple Gonal-F, Rekovelle, Bemfola, Puregon)<\/span><\/span>\n      <span class=\"stat-bubble\">\n        70%**\n        <svg class=\"bubble-ring\" viewbox=\"0 0 100 100\">\n          <circle cx=\"50\" cy=\"50\" r=\"48\" stroke=\"#528C9E\" stroke-width=\"4\" fill=\"none\"\/>\n        <\/svg>\n      <\/span>\n    <\/div>\n  <\/div>\n  <div class=\"stat-item\">\n    <div class=\"stat-box\">\n      <span class=\"stat-text\">rFSH+rLH <span class=\"small-brackets\">(Pergoveris)<\/span><\/span>\n      <span class=\"stat-bubble\">\n        88%**\n        <svg class=\"bubble-ring\" viewbox=\"0 0 100 100\">\n          <circle cx=\"50\" cy=\"50\" r=\"48\" stroke=\"#528C9E\" stroke-width=\"4\" fill=\"none\"\/>\n        <\/svg>\n      <\/span>\n    <\/div>\n  <\/div>\n<\/div>\n\n<!-- New description box -->\n<div class=\"description-box\">\n  <p>\n    * apr\u00e8s analyse des cellules cumulus de &gt; 1000 ovocytes (Van Vaerenbergh et al., 2021 ; Adriaenssens et al., 2019) ; ** apr\u00e8s analyse des cellules cumulus de &gt; 1000 ovocytes (Adriaenssens et al., 2025).\n  <\/p>\n<\/div>\n\n<style>\n.stats-container {\n  display: flex;\n  flex-direction: column;\n  gap: 25px;\n  max-width: 650px;\n  margin: 50px auto;\n}\n\n.stat-item {\n  display: flex;\n  justify-content: center;\n}\n\n.stat-box {\n  position: relative;\n  display: flex;\n  align-items: center;\n  height: 60px;\n  background: linear-gradient(to right, #F4AD31 0%, rgba(244,173,49,0) 100%);\n  border-radius: 15px;\n  padding: 0 20px;\n  width: 75%;\n  max-width: 500px;\n}\n\n.stat-text {\n  font-size: 20px;\n  font-weight: bold;\n  color: #333;\n  line-height: 30px;\n  flex: 1;\n}\n\n\/* Smaller font for text in brackets *\/\n.small-brackets {\n  font-size: 14px;\n  font-weight: normal;\n  color: #555;\n}\n\n.stat-bubble {\n  position: absolute;\n  right: -25px;\n  top: 50%;\n  transform: translateY(-50%);\n  width: 80px;\n  height: 80px;\n  background-color: white;\n  color: #528C9E;\n  font-size: 24px;\n  font-weight: bold;\n  display: flex;\n  justify-content: center;\n  align-items: center;\n  border-radius: 50%;\n  box-shadow: 0 2px 6px rgba(0,0,0,0.2);\n}\n\n.bubble-ring {\n  position: absolute;\n  top: 0;\n  left: 0;\n  width: 100%;\n  height: 100%;\n  pointer-events: none;\n}\n\n.description-box {\n  max-width: 500px;\n  margin: -45px auto 0; \/* closer to stats *\/\n  padding: 8px 12px;\n  border-radius: 0 0 12px 12px; \/* rounded only at bottom *\/\n  text-align: center;\n  font-size: 11px;\n  color: #333;\n  background-color: #fff;\n}\n<\/style>\n\n\n<h2 class=\"wp-block-heading\">R\u00e9sultats de nos \u00e9tudes<\/h2>\n<p><strong>Augmentation du taux de naissances vivantes<\/strong> <strong>et<\/strong> <strong>du taux de grossesses cliniques pour le SET<\/strong><\/p>\n<figure class=\"wp-block-image alignright size-full is-resized\"><a href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5.png\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1039 alignleft\" src=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5.png\" alt=\"clinical pregnancy rate increased significantly from 27 % to 63 % in the first fresh transfer cycle. Compared to day 5 SET \u2014 from 43 % to 63 %. Moreover, significant increase in live birth rate was proven between day 3 transfers.\" width=\"289\" height=\"222\" srcset=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5.png 962w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5-300x230.png 300w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5-768x588.png 768w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/09\/D3-and-D5-16x12.png 16w\" sizes=\"auto, (max-width: 289px) 100vw, 289px\" \/><\/a>\n<figcaption class=\"wp-element-caption\">\u00c9tude portant sur les r\u00e9sultats des patientes ayant b\u00e9n\u00e9fici\u00e9 d'un transfert \u00e9lectif d'un seul embryon (eSET) et d'une ICSI.<\/figcaption>\n<\/figure>\n<p>Les r\u00e9sultats de notre derni\u00e8re \u00e9tude interventionnelle prospective ont montr\u00e9 que dans le bras test Aurora niPCT\u2122 (\u00e9galement appel\u00e9 Aurora Test) avec transfert d'embryon unique (SET) au jour 3, le <strong>taux de grossesses cliniques a augment\u00e9 de mani\u00e8re significative <\/strong>, passant de 27 % \u00e0 63 % lors du premier cycle de transfert d'embryon frais. \u00c0 titre de comparaison, le SET au jour 5 est pass\u00e9 de 43 % \u00e0 63 %. De plus, <strong>une augmentation significative du taux de naissances vivantes<\/strong> a \u00e9t\u00e9 observ\u00e9e avec les transferts effectu\u00e9s au jour 3. Ces patientes \u00e9taient des patientes ayant b\u00e9n\u00e9fici\u00e9 d'une ICSI et d'une stimulation par HP-hMG. Dans les groupes t\u00e9moins, seule une \u00e9valuation morphologique a \u00e9t\u00e9 r\u00e9alis\u00e9e. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30627993\/\" target=\"_blank\" rel=\"noreferrer noopener\">En savoir plus \u2192<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Augmentation du taux de grossesse cumul\u00e9<\/strong><\/p>\n<p>Dans une \u00e9tude clinique ant\u00e9rieure, les taux cumulatifs ont \u00e9t\u00e9 suivis et le test Aurora niPCT\u2122 a \u00e9galement <strong>augment\u00e9 de mani\u00e8re significative le taux cumulatif de grossesse<\/strong> de 56 % \u00e0 78 % par rapport au groupe t\u00e9moin du jour 3 lorsque la patiente a subi des cycles cons\u00e9cutifs. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33608027\/\" target=\"_blank\" rel=\"noreferrer noopener\">En savoir plus \u2192<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Augmentation du taux de grossesse d\u00e8s la premi\u00e8re tentative et r\u00e9duction du d\u00e9lai de conception<\/strong><\/p>\n<p>&nbsp;<\/p>\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full is-resized\"><a href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to.png\"><img loading=\"lazy\" decoding=\"async\" width=\"822\" height=\"758\" src=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to.png\" alt=\"Results of clinical study showed a significantly shorter time-to-pregnancy. \" class=\"wp-image-1296\" style=\"width:300px;height:auto\" srcset=\"https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to.png 822w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to-300x277.png 300w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to-768x708.png 768w, https:\/\/fertiga.com\/wp-content\/uploads\/2025\/10\/time-to-13x12.png 13w\" sizes=\"auto, (max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px\" \/><\/a><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n<p>Les r\u00e9sultats de notre \u00e9tude clinique ont montr\u00e9 un <strong>d\u00e9lai de grossesse significativement plus court<\/strong> dans le groupe ayant b\u00e9n\u00e9fici\u00e9 du test Aurora niPCT\u2122 avec transfert d'embryons frais ou congel\u00e9s, comparativement au groupe t\u00e9moin. Chez les patientes ayant au moins deux embryons transf\u00e9rables, trois transferts suppl\u00e9mentaires ont \u00e9t\u00e9 n\u00e9cessaires dans le groupe t\u00e9moin pour obtenir le m\u00eame taux de grossesse clinique.\u00a0 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33608027\/\" target=\"_blank\" rel=\"noreferrer noopener\">En savoir plus \u2192<\/a><\/p>\n<p>&nbsp;<\/p>\n\n\n<h2 class=\"wp-block-heading\">Principe fond\u00e9 sur la science<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le test Aurora niPCT\u2122 est r\u00e9alis\u00e9 sur les cellules du cumulus entourant les ovocytes d'une patiente et repose sur la mesure de l'expression de g\u00e8nes sp\u00e9cifiques. <strong>Les cellules du cumulus sont pr\u00e9lev\u00e9es individuellement<\/strong> sur chaque ovocyte et l'ARN est extrait de ces cellules. Une PCR en temps r\u00e9el est effectu\u00e9e pour les g\u00e8nes pr\u00e9dictifs et deux g\u00e8nes de contr\u00f4le, permettant un classement quantitatif de tous les ovocytes. En savoir plus\u00a0:<\/p>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-1391f922-c552-481c-8f3b-96cfcf582df5\" href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/06\/Aurora-niPCT-Brochure.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Aurora niPCT\u2122 Brochure ENG<\/a><\/div>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-a6e48bad-241e-431c-97b6-86414e58f440\" href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/06\/DU-niPCT-Brochure_clinicians.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Aurora niPCT\u2122 Brochure NL<\/a><\/div>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-607f2cae-6e75-4bf4-9a98-d2af80f53753\" href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/06\/FR-niPCT-Brochure_clinicians.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Aurora niPCT\u2122 Brochure FR<\/a><\/div>\n\n\n\n<h1 class=\"wp-block-heading\">Aurora niPCT\u2122 est applicable pour<\/h1>\n\n\n\n<ul class=\"wp-block-list\">\n<li>transferts frais<\/li>\n\n\n\n<li>transferts congel\u00e9s<\/li>\n\n\n\n<li>cycles de don<\/li>\n\n\n\n<li>cong\u00e9lation sociale d'ovocytes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Le test Aurora niPCT\u2122 est r\u00e9alis\u00e9 sur les cellules du cumulus de tous les ovocytes d'une patiente et suit les m\u00eames analyses mol\u00e9culaires que pour une patiente ayant recours \u00e0 l'ICSI. Les ovocytes sont class\u00e9s par ordre de qualit\u00e9, et, ult\u00e9rieurement, les ovocytes les mieux class\u00e9s pourront \u00eatre utilis\u00e9s en priorit\u00e9. Les ovocytes doivent \u00eatre congel\u00e9s individuellement. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38295095\/\" target=\"_blank\" rel=\"noreferrer noopener\">En savoir plus \u2192<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Flux de service Aurora niPT\u2122<\/h2>\n\n\n<div class=\"wp-block-image wp-block-image aligncenter size-large\">\n<figure ><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"345\" src=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1-1024x345.png\" alt=\"\" class=\"wp-image-1641\" srcset=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1-1024x345.png 1024w, https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1-300x101.png 300w, https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1-768x259.png 768w, https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1-18x6.png 18w, https:\/\/fertiga.com\/wp-content\/uploads\/2026\/05\/Yellow-and-Orange-Illustrative-Self-Improvement-Infographic-Poster-1-1.png 1536w\" sizes=\"auto, (max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px\" \/><figcaption class=\"wp-element-caption\">Proc\u00e9dure pour un nouvel eSET<\/figcaption><\/figure>\n<\/div>\n\n<\/p>\n<p><!-- \/wp:post-content --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p>En cas d'\u00e9chec de la premi\u00e8re tentative de grossesse, les embryons surnum\u00e9raires vitrifi\u00e9s individuellement seront \u00e9galement transf\u00e9r\u00e9s selon le score Aurora.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p>Si un eSET congel\u00e9 est pr\u00e9vu, les \u00e9chantillons peuvent \u00eatre exp\u00e9di\u00e9s ult\u00e9rieurement, mais doivent arriver au laboratoire d\u2019analyses cliniques de Fertiga au moins une semaine avant le transfert.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:file {\"id\":1594,\"href\":\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/04\/Blue-and-White-Modern-Pharmacy-Lab-Flyer-7.pdf\",\"showDownloadButton\":false,\"displayPreview\":false,\"previewHeight\":670} --><\/p>\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-a2751fe1-b2a3-41ed-a0e0-3f5eb5fdbc22\" href=\"https:\/\/fertiga.com\/wp-content\/uploads\/2026\/04\/Blue-and-White-Modern-Pharmacy-Lab-Flyer-7.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">D\u00e9pliant sur le flux de travail en laboratoire d'embryologie plus d\u00e9taill\u00e9 <\/a><\/div>\n<p><!-- \/wp:file --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p>Pour plus d'informations sur la <strong>normalisation des conditions pr\u00e9-analytiques pour des tests fiables et non invasifs des cellules du cumulus avant implantation<\/strong>, <a href=\"https:\/\/fertiga.com\/fr\/contact-us\/\" type=\"link\" id=\"https:\/\/fertiga.com\/contact-us\/\">contactez-nous<\/a> pour obtenir un livre blanc.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\">Nos recherches<\/h2>\n<p><!-- \/wp:heading --><\/p>\n<p><!-- wp:list {\"ordered\":true} --><\/p>\n<ol class=\"wp-block-list\"><!-- wp:list-item --><\/p>\n<li>Adriaenssens T, Van Vaerenbergh I, Van Leuven W, Coucke W, Montenegro S, Zheng W, D\u2019Hooghe T, Van Landuyt L, De Munck N, Van Hecke E, Smitz J, Rosenthal A, Blockeel C<em>.<\/em>Live birth in patients stimulated with r-hFSH or r-hFSH: r-hLH is strongly associated with cumulus cell derived gene expression models.\u00a0Reprod Biol Endocrinol.\u00a02025;23(163). <a href=\"https:\/\/doi.org\/10.1186\/s12958-025-01480-2\">doi:1186\/s12958-025-01480-2<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Van Vaerenbergh I, Adriaenssens T, Coucke W, Van Landuyt L, Verheyen G, De Brucker M, Camus M, Platteau P, De Vos M, Van Hecke E, Rosenthal A, Smitz J. Improved clinical outcomes after non-invasive oocyte selection and Day 3 eSET in ICSI patients. Reprod Biol Endocrinol. 2021;19(1):26. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33608027\/\">1186\/s12958-021-00704-5<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Adriaenssens T, Van Vaerenbergh I, Coucke W, Segers I, Verheyen G, Anckaert E, De Vos M, Smitz J. Cumulus-corona gene expression analysis combined with morphological embryo scoring in single embryo transfer cycles increases live birth after fresh transfer and decreases time to pregnancy. J Assist Reprod Genet. 2019;36(3):433-443. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30627993\/\">1007\/s10815-018-01398-2<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Wathlet S, Adriaenssens T, Segers I, Verheyen G, Van Landuyt L, Coucke W, Devroey P, Smitz J. Pregnancy prediction in single embryo transfer cycles after ICSI using QPCR: validation in oocytes from the same cohort. PLoS One. 2013;8(4):e54226. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23573182\/\">1371\/journal.pone.0054226<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Wathlet S, Adriaenssens T, Segers I, Verheyen G, Janssens R, Coucke W, Devroey P, Smitz J. New candidate genes to predict pregnancy outcome in single embryo transfer cycles when using cumulus cell gene expression. Fertil Steril. 2012;98(2):432-9.e1-4. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22633264\/\">1016\/j.fertnstert.2012.05.007<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Wathlet S, Adriaenssens T, Segers I, Verheyen G, Van de Velde H, Coucke W, Ron El R, Devroey P, Smitz J. Cumulus cell gene expression predicts better cleavage-stage embryo or blastocyst development and pregnancy for ICSI patients. Hum Reprod. 2011;26(5):1035-51. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21372047\/\">1093\/humrep\/der036<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Adriaenssens T, Segers I, Wathlet S, Smitz J. The cumulus cell gene expression profile of oocytes with different nuclear maturity and potential for blastocyst formation. J Assist Reprod Genet. 2011;28(1):31-40. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20859762\/\">1007\/s10815-010-9481-9<\/a><\/li>\n<p><!-- \/wp:list-item --><\/p>\n<p><!-- wp:list-item --><\/p>\n<li>Adriaenssens T, Wathlet S, Segers I, Verheyen G, De Vos A, Van der Elst J, Coucke W, Devroey P, Smitz J. Cumulus cell gene expression is associated with oocyte developmental quality and influenced by patient and treatment characteristics. Hum Reprod. 2010;25(5):1259-70. doi: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20228394\/\">1093\/humrep\/deq049<\/a><\/li>\n<p><!-- \/wp:list-item --><\/ol>\n<p><!-- \/wp:list --><\/p>","protected":false},"excerpt":{"rendered":"<p>Not all oocytes are equal\u2026 but now you can tell which ones will thrive The Aurora niPCT\u2122 is the first clinically proven, non-invasive test that looks at what truly matters: the oocyte\u2019s biological potential itself. By analysing the cumulus cells that naturally surround and support the egg, Aurora niPCT\u2122 decodes the molecular signals of highest &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/\" class=\"more-link\">Continuer la lecture<span class=\"screen-reader-text\"> de &laquo;&nbsp;For healthcare providers&nbsp;&raquo;<\/span><\/a><\/p>","protected":false},"author":4,"featured_media":62,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-20","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>For healthcare providers - Fertiga<\/title>\n<meta name=\"description\" content=\"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"For healthcare providers - Fertiga\" \/>\n<meta property=\"og:description\" content=\"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Fertiga\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FertigaFertility\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T08:12:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fertiga.com\/wp-content\/uploads\/2018\/09\/shutterstock_324159947-1024x683.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/\",\"url\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/\",\"name\":\"For healthcare providers - Fertiga\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fertiga.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/shutterstock_324159947.jpg\",\"datePublished\":\"2018-08-31T08:43:31+00:00\",\"dateModified\":\"2026-06-04T08:12:33+00:00\",\"description\":\"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fertiga.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/shutterstock_324159947.jpg\",\"contentUrl\":\"https:\\\/\\\/fertiga.com\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/shutterstock_324159947.jpg\",\"width\":3000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/increased-live-birth-rate-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fertiga.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"For healthcare providers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/#website\",\"url\":\"https:\\\/\\\/fertiga.com\\\/\",\"name\":\"Fertiga\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fertiga.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/#organization\",\"name\":\"Fertiga\",\"url\":\"https:\\\/\\\/fertiga.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fertiga.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/fertiga.com\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/logo.png\",\"contentUrl\":\"http:\\\/\\\/fertiga.com\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/logo.png\",\"width\":487,\"height\":179,\"caption\":\"Fertiga\"},\"image\":{\"@id\":\"https:\\\/\\\/fertiga.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/FertigaFertility\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fertiga\\\/\",\"https:\\\/\\\/www.instagram.com\\\/fertilitybyfertiga\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"For healthcare providers - Fertiga","description":"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/","og_locale":"fr_FR","og_type":"article","og_title":"For healthcare providers - Fertiga","og_description":"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.","og_url":"https:\/\/fertiga.com\/fr\/increased-live-birth-rate-2\/","og_site_name":"Fertiga","article_publisher":"https:\/\/www.facebook.com\/FertigaFertility","article_modified_time":"2026-06-04T08:12:33+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/fertiga.com\/wp-content\/uploads\/2018\/09\/shutterstock_324159947-1024x683.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/","url":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/","name":"For healthcare providers - Fertiga","isPartOf":{"@id":"https:\/\/fertiga.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/#primaryimage"},"image":{"@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/#primaryimage"},"thumbnailUrl":"https:\/\/fertiga.com\/wp-content\/uploads\/2018\/09\/shutterstock_324159947.jpg","datePublished":"2018-08-31T08:43:31+00:00","dateModified":"2026-06-04T08:12:33+00:00","description":"Increased live birth and pregnancy rates with Aurora niPCT\u2122! This non-invasive preimplantation test can help you select the best embryo at the first try.","breadcrumb":{"@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fertiga.com\/increased-live-birth-rate-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/#primaryimage","url":"https:\/\/fertiga.com\/wp-content\/uploads\/2018\/09\/shutterstock_324159947.jpg","contentUrl":"https:\/\/fertiga.com\/wp-content\/uploads\/2018\/09\/shutterstock_324159947.jpg","width":3000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/fertiga.com\/increased-live-birth-rate-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fertiga.com\/"},{"@type":"ListItem","position":2,"name":"For healthcare providers"}]},{"@type":"WebSite","@id":"https:\/\/fertiga.com\/#website","url":"https:\/\/fertiga.com\/","name":"Fertiga","description":"","publisher":{"@id":"https:\/\/fertiga.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fertiga.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/fertiga.com\/#organization","name":"Fertiga","url":"https:\/\/fertiga.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fertiga.com\/#\/schema\/logo\/image\/","url":"http:\/\/fertiga.com\/wp-content\/uploads\/2018\/04\/logo.png","contentUrl":"http:\/\/fertiga.com\/wp-content\/uploads\/2018\/04\/logo.png","width":487,"height":179,"caption":"Fertiga"},"image":{"@id":"https:\/\/fertiga.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/FertigaFertility","https:\/\/www.linkedin.com\/company\/fertiga\/","https:\/\/www.instagram.com\/fertilitybyfertiga\/"]}]}},"_links":{"self":[{"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/pages\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":87,"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/pages\/20\/revisions"}],"predecessor-version":[{"id":1715,"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/pages\/20\/revisions\/1715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/media\/62"}],"wp:attachment":[{"href":"https:\/\/fertiga.com\/fr\/wp-json\/wp\/v2\/media?parent=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}